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Abstract
Background: Sudden cardiac death (SCD) is common after orthotopic heart
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transplant (OHT). No clear guidelines for implantable cardioverter defibrillator
(ICD) implantation in OHT patients at high risk for SCD currently exist.
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Objectives: To assess the safety, efficacy, and benefit of ICDs and resynchronization
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Methods: A retrospective multicenter cohort study within the United States.
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therapy post‐OHT. We also provide a systematic review of previous reports.
Patients with ICD post‐OHT between 2000 and 2020 were identified.
Results: We analyzed 16 patients from 4 centers. The mean standard‐deviation (SD)
age was 43 (18) years at OHT and 51 (20) years at ICD implantation. The mean (SD)
duration from OHT to ICD implantation was 9 (5) years. The mean (SD) left
ventricular ejection fraction (LVEF) was 35% (17%). There were 2 (13%)
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postprocedural complications: 1 hematoma and 1 death. Mean (SD) follow‐up was
24 (23) months. Survival rate was 63% (10/16) at 1 year and 56% (9/16) at 2 years,
with 6/7 of those who died having LVEF < 35% at the time of the ICD implantation.
Patients were more likely to receive appropriate therapy if their ICD was implanted
for secondary (5/8) rather than primary (0/8) prevention (p = .007). Of those
who did, 4 patients survived to 30 days post‐ICD therapy. Severe CAV was not
associated with the rate of appropriate therapy.
Conclusions: Beneficial outcomes were observed when ICDs were implanted for
secondary prevention only, and in patients with higher baseline LVEF. We also
observed benefits with resynchronization therapy.
KEYWORDS

advanced heart failure, appropriate therapy, heart transplantation, implantable cardioverter
defibrillator, sudden cardiac death
Abbreviations: BiV, biventricular; CAV, cardiac allograft vasculopathy; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; OHT,
orthotopic heart transplant; RBBB, right bundle branch block; SCD, sudden cardiac death.
#ICD utilization is safe and more beneficial when implanted for secondary prevention and in those with less severe cardiomyopathy in patients post #OHT who at risk for #SCD.
#CardioTwitter #EPeeps #Transplant
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| INTRODUCTION
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indication and year the ICD was implanted, type of ICD, side of
implantation, defibrillation threshold testing, and procedural compli-

Sudden cardiac death (SCD) accounts for around 10% of post‐

cations (hematoma, infection, lead dislodgment, perforation, tampo-

orthotopic heart transplant (OHT) mortality.1 The exact etiology and

nade, or death). Long‐term outcomes included ICD therapies

pathology leading to SCD are unknown. One study suggested that

delivered (both appropriate and inappropriate), follow‐up to the

the main findings at the time of SCD in OHT patients were asystole

response of the cardiac resynchronization therapy, device‐related

2

and pulseless electrical activity.

complications, and mortality.

The current guidelines designate a class IIb recommendation for

Statistical Package for Social Sciences (SPSS, version 27; IBM) was

implantable cardioverter defibrillator (ICD) implantation in post‐OHT

used for data analysis. Descriptive statistical analyses were obtained for

patients “with a heart transplant and severe allograft vasculopathy

all included study variables. Categorical variables are expressed as

with [left ventricle] LV dysfunction, an ICD may be reasonable if

frequency or percentage, whereas continuous variables are presented as

meaningful survival of greater than 1 year is expected.”3 It is unclear

mean and standard deviation. Univariate analysis was performed by

whether other regular guideline criteria for ICD implantation can be

using χ2 test or Fisher exact test for categorical variables and t test or

extrapolated from the general heart failure population to patients

the Mann–Whitney U test for continuous variables.

with OHT. In a national survey of 59 medical directors of heart

A review of the literature was performed using Medline and

transplant programs (response rate 56%), there was no explicit

PubMed databases between January 1990 and December 2020.

agreement on indications for ICDs in patients with OHT.4

Studies that addressed the safety, efficacy, and benefit of ICD

The benefit of primary or secondary prevention with ICDs in

implantation in post‐OHT patients were included. Abstracts and

post‐OHT patients who are at high risk of SCD is yet to be validated.

studies published in non‐English language were excluded. If a case

In this multicenter case series, we assessed the safety, efficacy,

series was published more than once, we included the more recent

and benefit of ICDs and resynchronization therapy in patients at high

study with the larger number of patients.

risk of SCD post‐OHT, and we provide a systematic review of
previous reports.
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| M E TH O D S

RESULTS
Patient baseline characteristics

This is a multicenter retrospective cohort study. We analyzed the

A total of 16 patients were included from 4 transplant centers (4 from

electronic health records of adult patients who received OHT at

Henry Ford Hospital, 7 from Indiana University, 4 from Mayo Clinic,

Henry Ford Hospital, Indiana University, Mayo Clinic, and The Ohio

and 1 from Ohio State University). The mean age (standard deviation

State University. Patients were included if they had a post‐OHT ICD

[SD]) at OHT was 43 ± 18 years (range: 12–67 years). Of 16 patients,

implantation between 2000 and 2020. The Institutional Review

4 were female (25%), 12 were male (75%), 13 were White, and 3 were

Boards at all participating institutions approved the study.

African American. The indication for transplantation was ischemic

Patients were considered at high risk for SCD based on the

cardiomyopathy in 6 patients, while the other 10 patients had

physicians' discretion at the time of ICD implantation. The indications

nonischemic cardiomyopathy. Other medical comorbidities are listed

for ICD implantation included primary prevention due to graft

in Table 1. There were 6 patients who had a device before

dysfunction with a depressed left ventricular ejection fraction

transplantation (5 ICD and 1 permanent pacemaker). Those devices

(LVEF) ≤ 35% or secondary prevention due to known ventricular

were explanted during or after OHT.

arrhythmia or high‐risk syncope attributed to an arrhythmic etiology.
Patient demographics, comorbid conditions, medications, transplantation, and post‐OHT ICD implantation data were collected.

3.2 |

Patient characteristics at implantation

Transplantation data included the cause of transplantation, patient
age at time of transplantation, and the date of surgery. ICD

The mean (SD) age at ICD implantation was 51 ± 20 years, and the

implantation data included graft LVEF, electrocardiogram data before

mean (SD) duration from OHT to implantation was 9 ± 5 years (range:

ICD implantation, and cardiac allograft vasculopathy (CAV) at the

0.1–16 years). Table S1 includes the characteristics of every patient

time of implantation. CAV criteria was based on the International

included in this study.

5

Society for Heart and Lung Transplantation. Significant CAV was

At the time of implantation, 9 patients had significant CAV, 8 of

defined as ≥50% stenosis in ≥1 epicardial artery. Severe CAV was

which were considered severe. The average LVEF was 35% ± 17%.

defined as ≥70% stenosis in the proximal left main or proximal left

None of the patients had any significant valvular disease. All the

anterior descending artery, ≥70% stenosis in ≥2 epicardial vessels, or

patients were in sinus rhythm and 1 patient was atrial paced.

severe diffuse CAV.5 Significant valvular disease was defined by any

The mean (SD) QRS duration was 137 ± 34 ms, and 4 patients had a

valvular disease (stenosis/regurgitation) assessed as contributing to

wide QRS duration >150 ms—two with left bundle branch block

the observed cardiomyopathy. Procedural data included the

(LBBB) and two with right bundle branch block (RBBB).
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TABLE 1

Baseline characteristics

Variable

3

Six single‐chamber, 6 dual‐chamber, and 3 biventricular (BiV)
Results (N = 16)

devices were implanted. One additional His‐pacing approach was
used after an unsuccessful BiV attempt. All but 2 patients had

Sex, no. (%)

their device implanted on the left side (the 2 exceptions because
Female

4 (25%)

Male

12 (75%)

of left‐sided venous stenosis and extreme tortuosity from devices
before OHT). Defibrillation threshold testing was performed in
2/8 and 7/8 patients in which the indication for implantation was

Indication for OHT, no. (%)
Ischemic cardiomyopathy

6 (38%)

Nonischemic cardiomyopathy

10 (42%)

for primary and secondary prevention, respectively. There were 2
procedural complications, including 1 hematoma that required
evacuation, and 1 death. The patient who developed a hematoma

Age at OHT, mean ± SD, years

43 ± 18

was on home subcutaneous enoxaparin for deep vein thrombosis

Age at ICD implantation post‐OHT, mean ± SD

51 ± 20

treatment. The patient who died had end‐stage heart failure and

Duration from OHT to ICD implantation,
mean ± SD, years

9±5

Left ventricular ejection fraction, mean% ± SD

the CRT device was considered as a last salvage attempt. He
developed pulseless electrical activity arrest peri‐procedure that

35% ± 17%

Comorbid Conditions, no. (%)

was attributed to advanced cardiomyopathy (LVEF 19%, RBBB
with QRS duration 167 ms). The device had normal function, and
there were no signs of effusion or other signs of perforation

Hypertension

15 (94%)

Diabetes mellitus

3 (19%)

Significant CAV

9 (56%)

Severe CAV

8 (50%)

Coronary artery disease

11 (69%)

The survival rate for all patients was 63% (10/16) at 1 year and 56%

Atrial fibrillation

2 (13%)

(9/16) at 2 years. The mean (SD) follow‐up was 24 ± 23 months with

Cerebrovascular disease

0 (0%)

Obstructive sleep apnea

4 (25%)

Chronic kidney disease

8 (50%)

postprocedure.

3.3 |

Long‐term follow‐up

6 of 16 patients alive at the time of data collection.
Five patients received appropriate ICD therapies for ventricular
arrhythmias. Of these, 4 patients survived for 30 days post‐ICD
therapy (median [SD] 77 ± 67 months, range: 1–142 months),
whereas 1 patient was hospitalized and died within 24 h of the first

ECG characteristics at ICD implantation

ICD therapy from advanced cardiomyopathy and cardiogenic shock

Sinus rhythm

15 (94%)

Atrial paced rhythm

1 (6%)

QRS duration, mean ± SD, ms

137 ± 34

(range: 0–142 months). Patients were more likely to receive

Left anterior fascicular block, no. (%)

3 (19%)

appropriate ICD therapy if the ICD device was implanted for

Incomplete right bundle branch block, no. (%)

4 (25%)

Complete right bundle branch block, no. (%)

8 (50%)

Left bundle branch block, no. (%)

2 (13%)

(LVEF was 19%). The mean (SD) time from first appropriate ICD
therapy to the last follow‐up date available was 48 ± 64 months

secondary prevention (5/8) rather than for primary prevention (0/8)
(p = .007). No other comorbid conditions were significantly associated
with the rate of appropriate therapy (odds ratio: 0.56, 95%
confidence interval: 0.07–4.76, p = .59).

Medications, no. (%)
Beta‐blocker

with appropriate therapy. To note, severe CAV was not associated

13 (81%)

ACEi, ARB, ARNi

9 (56%)

Anticoagulation

3 (19%)

Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors;
ARB, angiotensin receptor blockers; ARNi, angiotensin receptor neprilysin
inhibitor; CAV, cardiac allograft vasculopathy; ECG, electrocardiogram;
ICD, implantable cardioverter defibrillator; OHT, orthotopic heart
transplantation, SD, standard deviation.

The mean (SD) follow‐up from ICD implantation to last follow‐up
for patients who did not receive any appropriate device therapy was
26 ± 27 months. Three patients received inappropriate shocks for
supraventricular arrhythmias (1 atrial tachycardia) at a rate above the
therapy threshold, and 1 patient developed a pocket infection 4 years
after implantation that required extraction and reimplantation of a
new device.
Excluding the cardiac resynchronization patients, patients with
an LVEF ≤ 35% were less likely to receive appropriate ICD therapy or
survive at 1 year post‐ICD implantation (Table 2). As noted above, 1

The indication for ICD implantation was primary prevention in the

patient with severely reduced LVEF received appropriate ICD

8 patients assessed as having an increased risk of SCD (7 with

therapy and died within 7 months of ICD therapy. Patient

LVEF ≤ 35% and 1 patient with severe CAV and rejection with

characteristics and outcomes according to the indication for ICD

LVEF = 60%) and for secondary prevention in the remaining 8 patients.

implantation are listed in Table 3.
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T A B L E 2 Characteristics of patients according to left ventricular ejection fraction excluding patients who received resynchronization
therapy (biventricular or His‐Pacing therapy)
Ejection fraction ≤35%
Total n = 6

Ejection fraction >35%
Total n = 6

Age, mean ± SD, years

44 ± 15

35 ± 18

Duration from OHT to ICD, years

10 ± 4

9±6

Age at ICD Implantation, mean ± SD, years

54 ± 15

44 ± 21

Hypertension

6 (100%)

5 (83%)

Diabetes mellitus

0 (0%)

1 (17%)

Significant CAV

5 (83%)

2 (33%)

Severe CAV

5 (83%)

1 (17%)

Coronary artery disease

4 (67%)

4 (67%)

Atrial fibrillation

1 (17%)

0 (0%)

Cerebrovascular disease

0 (0%)

0 (0%)

Obstructive sleep apnea

1 (17%)

3 (50%)

Chronic kidney disease

3 (50%)

2 (33%)

Survival at 1 year post‐ICD implantation, no. (%)

2 (33%)a

5 (83%)

Survival at 2 years post‐ICD implantation, no. (%)

1 (16%)

5 (83%)

Time from ICD implantation to last follow‐up, mean ± SD,
months

14 ± 10

28 ± 30

Survival after first appropriate ICD therapy

1 Patient received appropriate ICD
therapy and was deceased 7
months after the ICD therapy

Patient 1 received appropriate ICD
therapy and is still alive 12 years after
the first ICD therapy
Patient 2 received appropriate ICD
therapy and was deceased on the
same day of the ICD therapy
Patient 3 received appropriate ICD
therapy and was deceased 1 month
after the first ICD therapy
Patient 4 received appropriate ICD
therapy and was deceased 8 years
after the first ICD therapy

Primary prevention

2 (33%)

2 (33%)

Secondary prevention

4 (66%)

4 (66%)

Indication for pacing

0

1 (16%)

Appropriate ICD therapy

1 (16%)

4 (66%)

Inappropriate ICD therapy

2 (33%)

1 (16%)

Abbreviations: CAV, cardiac allograft vasculopathy; CI, confidence interval; ICD, implantable cardioverter defibrillator; OHT, orthotopic heart
transplantation; SD, standard deviation.
Patients who have an LVEF ≤ 35% have an odds ratio (95% CI) of 0.1 (0.006–1.544), p = .079 to survive at 1 year post‐ICD implantation.

a

3.4

| Cardiac resynchronization therapy

failure at the time of implantation. The mean follow‐up for the
surviving patients was 45 ± 14 months.

There were 3 patients who had a biventricular ICD implanted and

The patient who received a His‐bundle pacing had LBBB, and the

1 patient had a His‐bundle pacing lead placed after an unsuccessful

ejection fraction improved from 25% to 62% and was published as a

BiV device implantation. At the time of this writing, 3 of these

case report abstract.6

patients were still alive and 1 had a peri‐procedural pulseless

The LVEF recovered to baseline (from 20% to 45%) in the second

electrical activity cardiac arrest. The latter had end‐stage heart

patient who had a LBBB, and the LVEF remained unchanged at 30%

MASKOUN
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T A B L E 3 Characteristics of patients
according to indication of ICD
implantation

Primary prevention
Total n = 8

Secondary prevention
Total n = 8

Age, mean ± SD, years

40 ± 22

45 ± 15

Duration from OHT to ICD, years

8±4

9±6

Age at ICD Implantation, mean ± SD, years

48 ± 21

54 ± 19

Hypertension

7 (88%)

8 (100%)

Diabetes mellitus

2 (25%)

1 (13%)

Significant CAV

4 (50%)

5 (63%)

Severe CAV

4 (50%)

4 (50%)

Coronary artery disease

6 (75%)

5 (63%)

Atrial fibrillation

2 (25%)

0 (0%)

Cerebrovascular disease

0 (0%)

0 (0%)

Obstructive sleep apnea

1 (13%)

3 (38%)

Chronic kidney disease

5 (63%)

3 (38%)

Survival at 1 year post‐ICD implantation, no. (%)

5 (63%)

5 (63%)

Survival at 2 years post‐ICD implantation, no. (%)

5 (63%)

4 (50%)

Appropriate ICD therapy

0 (0%)

5 (63%)

Inappropriate ICD therapy

1 (13%)

2 (25%)

5

Abbreviations: CAV, cardiac allograft vasculopathy; ICD, implantable cardioverter defibrillator;
OHT, orthotopic heart transplantation; SD, standard deviation.

in the second patient with a RBBB (QRS duration of 168 ms) at

patients received appropriate ICD therapy, and the observed

3.5 years of follow‐up. All 4 patients had their ICDs implanted as part

benefit was from CRT‐P therapy.

of primary prevention management. None of these patients received
any appropriate or inappropriate ICD therapies.

Cardiac transplantation is the gold standard in the treatment of
chronic stage D heart failure refractory to heart failure guideline‐
directed medical therapy.11 SCD is a common cause of death in patients
after OHT, reported at 0.7%,12 2.3%,12 and 10%1 over a follow‐up of

| Literature review

3.5

1 year,12 4.7 years,12 and 6.5 years,1 respectively. While the incidence of
overall and non‐SCD posttransplantation mortality has decreased, SCD

We identified three case series of transvenous ICD implantation post‐
7–9

OHT.

10

The study by Ptaszek et al.

was excluded as these subjects
8

mortality has not.1 The major risk factors for SCD are LVEF < 40%,1,13
allograft rejection,12,14 including CAV,12–14 and higher donor age.1

were included in the case series by Tsai et al. We excluded the study by

Vaseghi et al.2 reported that the findings at the time of SCD in OHT

McDowell et al.4 as well due to our concern that some of their subjects

patients were asystole in 34%, pulseless electrical activity in 20%, and

8

might be included in the case series by Tsai et al. Additionally, that report

ventricular fibrillation in 10%. This suggests that ICD might be beneficial

did not include procedure/device‐related complications, nor did it state

in reducing SCD and improving survival in some OHT patients.

the outcome after appropriate device therapies. The results of the case
series are summarized and combined in Table 4.

Scant literature exists on the use of ICD in patients with
OHT.7–9,15–18 The 2017, AHA/ACC/HRS guidelines stated that ICD use
after OHT for patients with severe allograft vasculopathy with LV
dysfunction may be reasonable if meaningful survival of greater than 1

4

| DISC US SION

year is expected. This is a class IIb indication (level of evidence is
B‐NR).3 There are no further specific guidelines for ICD implantation in

Our retrospective multicenter study suggests that using ICDs in

OHT recipients. However, whether the standard guideline criteria for ICD

heart transplant recipients who are at high risk for SCD may be

implantation are appropriate for patients with OHT remains unclear.

safe and effective if implanted for secondary prevention in

There have been 4 published cases of heart transplant patients who had

patients without severe cardiomyopathy. In this small series,

SCD despite having functioning ICDs.15,16 Furthermore, while ICDs have

patients who received appropriate and life‐saving device thera-

been shown to decrease mortality in patients waiting for their first heart

pies all had ICDs implanted for secondary prevention purposes.

transplantation,19 a similar decrease has not been seen for patients who

We also observed benefits from CRT‐D, however, none of these

have had OHT and are waiting for a second transplant.17 However,

29/7

44 ± 14 years

N/A

8 ± 6 years

Severe CAV (n = 12, 33%)
Unexplained syncope (n = 9, 25%)
Severe CAV (n = 8, 80%)
Secondary prevention for
ventricular arrhythmia
Secondary prevention for
(n = 8, 22%)
unexplained syncope
Severe LV dysfunction
(n = 2, 20%)
(LVEF ≤ 35%) (n = 7, 19%)

26/36

Male/female

Average age at OHT

Indications for OHT

Mean Duration from
OHT to ICD
implantation

Indications for
placement

Allograft CAV

45 ± 12%

123 ± 36 ms

51 ± 26 months

All patients: 21 ± 9 J

17% (n = 6)

Mean QRS duration

Mean follow‐up

DFT testing at ICD
implantation

Complication rate

BiV ICD 6

Dual chamber ICD 20

LVEF at ICD placement

ICD device type

36

Number of patients

Single chamber ICD 10

ICD implantation between 1995
and 2005, Five Centers, USA

Years/location

Rubin et al.9

0% (n = 0)

NA

29 ± 12 months

111 ± 23 ms

49 ± 12%

Not mentioned

8/10

16 ± 6 years

Ischemic CM 40% (4)

Dilated CM (5), Myocarditis (1)

39 ± 14 years

8/2

10

17% (n = 3)

Not available

Not available

Not mention

40 ± 22%

Subcutaneous ICD 1
BIV ICD 2

Dual chamber ICD 5

Single chamber ICD 10

12.5% (n = 2) + Late Complication
6% (n = 1)

9/16

24 ± 23 months

137 ± 34 ms

35 ± 17%

BiV ICD 3 + 1 His‐Pacing

Dual chamber ICD 6

Single chamber ICD 6

9/16

12/80 (15%)

40 ± 13 monthsa

125 ± 8 msa

42 ± 5%a

BiV ICD 11 + 1 His‐
Pacing

Dual chamber ICD 31

Single chamber ICD 26

52/80

Severe CAV (n = 23)
Syncope (n = 11)
Primary prevention
(n = 28)
Secondary prevention
(n = 21)
Severe CAV (n = 1)
Syncope with positive EP
study (n = 1)
Primary prevention for severe LV
dysfunction (n = 7)
Secondary prevention for
ventricular arrhythmia (n = 7)

Secondary prevention (n = 4, 22%)
Low LVEF (n = 5, 28%)
CAV (n = 1, 6%)
Syncope + CAV (n = 1, 6%)
Low LVEF + CAV (n = 7, 39%)

9/18

8.5 ± 3 yearsa

Ischemic CM (10/26)

Nonischemic CM
(16/26)

45 ± 5 yearsa

49/13

80

Multicenter, Ireland
and USA

Combined

9 ± 5 years

Ischemic CM (6/16)

Nonischemic CM (10/16)

43 ± 18 years

12/4

16

ICD implantation between 2000
and 2020, Four Centers, USA

Our study

5.4 years

N/A

54

15/3

18

ICD for OHT done between 1983 ICD after OHT 2005–2020. Single
and 2012, Single Center, Ireland
center, Columbia university, USA

Tsai et al.8

Study
Neylon et al.7

Summary of case series for ICD placement in patients with OHT

Study findings

TABLE 4

6
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Pocket site infection (n = 2)
Displaced lead (n = 2)
Pocket hematoma (n = 1)
Lead fracture (n = 1)

22 Shocks for 10 patients:
12 Appropriate shocks for 8
patients (all effective)
10 Inappropriate shock for 3
patients

32 Survived (including 3 patients
who received 2nd transplant)
7/8 Patients with appropriate
shocks were still alive

Complications details

ICD therapy

Outcome

5 Patients with appropriate
shocks
3 Patients with inappropriate
shocks

Post‐ICD survival:
1 year: 63% (10/16)
2 years: 56% (9/16)
6/16 still alive (follow‐up was
24 ± 23 months)
5 Patients received appropriate
ICD therapy, of which 4 are
still alive 30 days post‐ICD
therapy

1 × Appropriate and effective ATP 1 Appropriate therapy
1 × Appropriate and effective shock 2 Inappropriate therapies
15 No therapies
No Inappropriate shocks

Survival 1‐year
post‐ICD was 56%

Causes of death 1‐year post‐ICD
included: progressive CAV/allograft
failure (terminal PEA), infection
(asystole), and subdural hemorrhage

9 Survived

Total n = 80
sCAV n = 51

Outcome Subgroup by
Severe CAV

Appropriate therapy
Secondary prevention (6/12) vs. Primary prevention (0/22), p < .001

Appropriate therapy
sCAV (n = 11, 22%) vs. no sCAV (n = 5, 17%), p = .642

Appropriate therapy
LVdysfx (n = 5, 15%) vs. no LVdysfx (n = 11, 23%), p = .364

Inappropriate therapy
Secondary prevention (2/12) vs. Primary prevention
(3/22), p = .812

Inappropriate therapy
sCAV (n = 7, 14%) vs. no sCAV (n = 1, 3%), p = .141

Inappropriate therapy
LVdysfx (n = 2, 6%) vs. no LVdysfx (n = 6, 13%), p = .325

a

Weighted average and standard deviations.

Abbreviations: BiV, biventricular; CAV, cardiac allograft vasculopathy; CM, cardiomyopathy; DFT, defibrillation thresholds; ICD, implantable cardioverter defibrillator; LV, left ventricle; LVdysfx, severe left
ventricular dysfunction LVEF, <35%; LVEF, left ventricular ejection fraction; OHT, orthotopic heart transplant, PEA, pulseless electrical activity; sCAV, severe cardiac allograft vasculopathy; US, United States;
VF, ventricular fibrillation.

Outcomes by indication Total 34 (HF and Rubin et al.)
for ICD implantation

Total n = 80
LV ≤ 35% n = 33

Outcome Subgroup by
LVE ≤ 35%
All studies

See case series for other
specifics

16 Patients received
appropriate therapy
15 Patients received
inappropriate
therapy

See case series specifics

Pocket infection (n = 1)
Hematoma (n = 1)
Deep vein thrombosis (n = 1)
PEA arrest (n = 1)

Venous obstruction (n = 1)
Lead fracture (n = 1)
Infection requiring system
extraction (n = 1)

None

Combined

Our study

Rubin et al.9

Study
Neylon et al.7

4 Deaths (3 deaths from stage D 1 Death despite effective shocks
for VF with subsequent
heart failure and 1 death from
electromechanical dissociation
sepsis)

Tsai et al.8

(Continued)

Study findings

TABLE 4

MASKOUN
ET AL.
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F I G U R E 1 Forrest plot with variables
associated appropriate shocks

TABLE 5

Implantable cardioverter defibrillator characteristics

Characteristic

Number (%)

(79%). In the series by Tsai et al.,8 the causes of ICD implantation
followed a temporal distribution: SCD was the most common reason
<1‐year post‐OHT; graft failure and sudden death occurred 2–4

Side of ICD implantation

years post‐OHT; and severe graft vasculopathy was seen >5 years
Left

14 (87)

Right

2 (13)

post‐OHT. In our series, only 1 patient had the ICD implanted within
1 year of OHT, and the indication was for secondary prevention.
In the series by Tsai et al.,8 all the patients with appropriate

Type of ICD

therapy had allograft vasculopathy compared to only 64% of patients

Single chamber

6 (38)

Dual chamber

6 (38)

Biventricular

4 (24)

therapy. This is also true when all cases from studies with available

Single coil

7 (44)

data (our study, Tsai, and Neylon) are combined (Table 4) with no

Dual coil

9 (56)

Defibrillation threshold testing

9 (56)

Complications at implantation

2 (12.5)

with inappropriate shocks. This was not the case in our case series,
where we observed no correlation between CAV and appropriate

difference in appropriate or inappropriate therapies in patients with
severe CAV. No statistically significant difference in appropriate/

Hematoma

1

Cardiac arrest

1

inappropriate therapies was observed in patients with or without severe
LV dysfunction (LVEF ≤ 35%) within the pooled data analysis (Table 4
and Figure 1). In our series, all the patients with appropriate therapies
had their ICD implanted for secondary prevention and secondary
prevention was significantly associated with appropriate shocks (Table 4

Late complications

and Figure 1). The guidelines advocate for ICD implantation for SCD
1 (6)

prevention if a meaningful survival of greater than 1 year is expected.3

Appropriate ICD therapy

5 (31)

In our series, patients who were deemed to be candidates for ICD

Inappropriate ICD therapy

3 (19)

therapy did not have optimal survival if their LVEF ≤ 35%. This may be

Pocket infection (4 years from ICD implantation)

because cardiomyopathy advances more rapidly among patients with
Abbreviation: ICD, implantable cardioverter defibrillator.

OHT. Therefore, an earlier intervention is warranted for ICD implantation at higher than traditional indications for ejection fraction (mild to
moderately decreased LVEF) which may indicate severe graft mal-

patients who have had OHT and are awaiting a second heart transplant

function with potential irreversible and accelerated graft failure in this

are at an overall higher risk of complications, and compared to patients

unique cohort of patients.

who are waiting for a first OHT, they experience twice the mortality both
20

during the wait list period and after the second transplant.

There are only 2 published case series that have described ICD
7,8

outcomes in patients with OHT.

The findings of the 2 series are

In the study by Neylon et al.,7 no procedure‐related or follow‐up
complications, including late infection, were seen, and no inappropriate
shocks occurred. The complication rate observed by Tsai et al.8 was
around 17% (Table 4), which is similar to our complication rate (12.5%)

summarized in Table 4 and Figure 1 alongside our case series, totaling

(Tables 5 and 3), in addition to 1 late pocket infection 4 years from ICD

80 patients. In the combined series, most of the patients were men

implantation. The higher than expected complication rate for ICD
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implantation21 may be due to the patients' overall poor clinical status,

survival postgraft dysfunction. Patients with secondary prevention

comorbidities, and immunosuppression. There is 1 case report that

indication were more likely to benefit from ICD therapy. Whether routine

describes a first subcutaneous ICD that was placed in the immediate

primary or secondary prevention with ICDs is indicated in high‐risk post‐

post‐transplantation period after acute cellular rejection and cardiac

OHT patients requires further validation. The observed benefits in patients

arrest.22 This approach may theoretically lower the rate of infection.22

with CRT‐Ds is likely due to resynchronization pace therapy as none of

Two of our patients had their ICDs implanted on the right side, and both of

these patients received appropriate shock therapy. We suggest a “lower”

these patients had prior left‐sided explanted devices following the OHT.

risk of SCD criteria (e.g., higher LVEF cutoff than non‐OHT patients, and/

We therefore recommend a venous patency assessment before planned

or less significant CAV) to guide ICD utilization in patients post‐OHT. ICD

ICD implantation in OHT patients with history of an explanted device

implantation in these patients, especially for primary prevention, warrants

following their OHT surgery.

careful evaluation of risks and benefits and shared decision‐making.

8

In the Tsai et al. series, 6 out of 36 patients received a BiV ICD,
but none of these patients had a LBBB. In a national survey of 59
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for heart transplant recipients, even in the presence of heart failure
symptoms and a wide QRS on the electrocardiogram.4 In our case
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the implant procedure. As noted, this patient had severe end stage
heart failure. An additional patient had a His‐bundle pacing instead of
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period of 3.5 years. In a recently published study, His‐CRT provided

Mahmoud Houmsse

comparable clinical and physical improvement to BiV‐CRT for heart failure

Fatima Ezzeddine

https://orcid.org/0000-0001-9128-6128
https://orcid.org/0000-0002-5446-3786
http://orcid.org/0000-0002-5897-9464
http://orcid.org/0000-0003-3821-3872
http://orcid.org/0000-0002-6204-4557

patients with LBBB.23 Therefore, for patients who meet class I or IIa
indication for BiV‐CRT or His‐CRT pacing after OHT, we anticipate a good
CRT outcome as those without OHT.
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